drugset / Trial / NCT06271564

Effectiveness of Topical Magnetite Zinc Oxide Composite Nanoparticles in the Management of Oral Potentially Malignant Lesions

NCT06271564 ↗

Phase 1/2 Completed 24 enrolled Ain Shams University
RandomizedParallel-groupTriple-blindTreatment

Summary

ZnO nanoparticles are now being widely researched for their anticancer properties. They show relatively high biocompatibility. They also show selective cytotoxicity against cancerous cells in in vitro condition compared with other nanoparticles. They can be further surface engineered to show increased selective cytotoxicity. The synthesis process of ZnO nanoparticles is relatively easy, with a wide variety of methods. Owing to these different methods of synthesis, their size and size distribution can be easily controlled. One of the novel methods of synthesis of ZnO is Magnetite ZnO-Fe3O4 Composite Nanoparticles.Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell.

Timeline

Start
2024-02-29
Primary completion
2025-12-30
Completion
2026-04-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnetite ZnO Composite Nanoparticles Unknown 5 % Topical

Indications